Clinical Trial

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

Study acronym: PTCy-PMAT
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This randomized clinical trial will evaluate two approaches of GvHD prophylaxis; the standard of care GVHD prophylaxis regimen (methotrexate/calcineurin inhibitors) and post-transplant cyclophosphamide with calcineurin inhibitors for their efficacy as a new GVHD prophylaxis strategy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-03-17; most recent amendment 2025-03-12.
Trial Details
NCT Number NCT04314219
Lead Sponsor King Faisal Specialist Hospital & Research Center
Conditions Acute Lymphoblastic Leukemia (ALL) in Complete Remission, Acute Myeloid Leukemia (AML) in Remission
Enrollment 264 participants
Start Date 2021-08-15
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-13